Active	Status	Sponsor type	Region	Phase	Filter
8 Active 14 Inactive 22 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Malek, Ehsan
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI	Recruiting	3	1100	Canada, US	Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20	SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP	Multiple Myeloma	07/29	07/40
NCT02833610: A Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency	Completed	2	55	US	Denosumab Q4W, Xgeva, Prolia	Massachusetts General Hospital, Amgen, Emory University, University of Rochester, University Hospitals Cleveland Medical Center	Multiple Myeloma	03/23	03/23
Lazarus, Hillard
No trials found
Callahan, Joyce
No trials found